胰臟癌治療市場規模、佔有率、成長分析，按治療類型、按診斷、按給藥途徑、按最終用戶、按分銷管道、按地區 - 行業預測，2025-2032 年

2023 年全球胰臟癌治療市場規模價值 28 億美元，預計將從 2024 年的 32 億美元成長到 2032 年的 92.5 億美元，預測期間（2025-2032 年）的複合年成長率為 14.2%。

據美國癌症協會稱，胰腺癌約占美國所有癌症病例的 3%，由於這種棘手疾病的發病率不斷上升，預計未來幾年胰腺癌治療市場將大幅成長。胰臟癌通常在晚期才被發現，因此對有效治療方案的需求日益增加。主要症狀包括黃疸和體重減輕，風險因素包括糖尿病和接觸某些化學物質。隨著企業在感染疾病後重組業務並克服社會隔離和遠距工作的最初影響，市場擴張也隨之加速。隨著我們對腫瘤特徵的了解不斷加深，個人化的治療方法在治療這種惡性癌症方面可能會變得越來越重要。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

胰臟癌治療市場規模（依治療類型分類）

• 市場概況
• 化療
• 標靶治療
• 免疫療法
• 荷爾蒙療法
• 其他

胰臟癌治療市場規模（依診斷）

• 市場概況
• 血液檢查
• 切片檢查
• 影像檢查
• 其他

胰臟癌治療市場規模（依給藥途徑）

• 市場概況
• 口服
• 腸外
• 其他

胰臟癌治療市場規模（按最終用戶分類）

• 市場概況
• 醫院
• 專科門診
• 居家護理
• 其他

胰臟癌治療市場規模（按通路分類）

• 市場概況
• 醫院藥房
• 零售藥局
• 網路藥局
• 其他

胰臟癌治療市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Sanofi SA（France）
• AstraZeneca PLC（UK）
• GlaxoSmithKline plc（UK）
• Johnson & Johnson（USA）
• Abbott Laboratories（USA）
• Sun Pharmaceutical Industries Ltd.（India）
• Cipla Ltd.（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Lupin Ltd.（India）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Valeant Pharmaceuticals International（Canada）
• Merck & Co., Inc.（USA）
• Bristol Myers Squibb（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Sinopharm（China）
• Shanghai Fosun Pharmaceutical（Group）Co., Ltd（China）
• EMS SA（Brazil）

結論和建議

Global Pancreatic Cancer Treatment Market size was valued at USD 2.8 billion in 2023 and is poised to grow from USD 3.2 billion in 2024 to USD 9.25 billion by 2032, growing at a CAGR of 14.2% during the forecast period (2025-2032).

The pancreatic cancer treatment market is poised for significant growth in the coming years, driven by the rising incidence of this challenging disease, which accounts for approximately 3% of all cancer cases in the U.S., according to the American Cancer Society. With pancreatic cancer often detected at advanced stages, the demand for effective treatment options is on the rise. Key symptoms include jaundice and weight loss, and risk factors range from diabetes to exposure to certain chemicals. The market's expansion is further bolstered by companies restructuring operations post-COVID-19, overcoming earlier disruptions from social isolation and remote work. As understanding of tumor characteristics deepens, personalized treatment approaches will become increasingly critical in managing this aggressive form of cancer.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pancreatic Cancer Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pancreatic Cancer Treatment Market Segmental Analysis

Global Pancreatic Cancer Treatment Market is segmented by Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel and region. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Hormone Therapy and Others. Based on Diagnosis, the market is segmented into Blood Test, Biopsy, Imaging Tests and Others. Based on Route of Administration, the market is segmented into Oral, Parenteral and Others. Based on End-User, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.Based on diagnosis, the market is segmented into blood test, biopsy, imaging tests, others. By route of administration, the market is segmented into oral, parenteral, and others. By end-user, the market is segmented into hospitals, specialty clinics, homecare, and others. By distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. Based on region, the pancreatic cancer treatment market segmentation spans North America, Europe, Asia-Pacific, South America, and MEA.

Driver of the Global Pancreatic Cancer Treatment Market

The global market for pancreatic cancer treatment is poised for significant growth primarily due to the rising prevalence of cancer and the corresponding demand for specialized care. With an increasing number of diagnoses linked to genetic factors such as BRCA2 gene mutations, Lynch syndrome, and familial atypical mole-malignant melanoma (FAMMM) syndrome, there is a heightened familial risk for cancer. Additionally, the growing rates of diabetes and obesity contribute to the escalating incidence of pancreatic cancer. Enhanced healthcare spending is also a vital driver, as it improves the existing infrastructure and promotes the development of treatment options. Government initiatives aimed at bolstering healthcare funding further influence market dynamics, paving the way for advancements in pancreatic cancer treatment solutions.

Restraints in the Global Pancreatic Cancer Treatment Market

The global pancreatic cancer treatment market is expected to encounter several restraints that could hinder its growth trajectory. Chief among these is the high cost of treatment, which poses a significant barrier for patients seeking care. Additionally, in many emerging regions, inadequate healthcare infrastructure and a scarcity of skilled medical professionals will further complicate access to effective treatment options. Between 2023 and 2030, stringent regulatory requirements coupled with insufficient public awareness about pancreatic cancer and available therapies are likely to further restrict market expansion, thereby creating challenges for stakeholders aiming to improve patient outcomes in this critical area.

Market Trends of the Global Pancreatic Cancer Treatment Market

The Global Pancreatic Cancer Treatment market is witnessing a significant surge driven by intensifying research and development (R&D) initiatives aimed at innovative therapeutic solutions. With a notable rise in drug discoveries and regulatory approvals, the landscape is becoming increasingly favorable for the introduction of novel treatments. These advancements not only enhance treatment efficacy but also broaden the range of options available to healthcare providers and patients. Furthermore, ongoing collaborations between pharmaceutical companies and research institutions are expected to facilitate the rapid development of targeted therapies, thereby propelling the market's growth trajectory and addressing the critical unmet needs in pancreatic cancer care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Pancreatic Cancer Treatment Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Hormone Therapy
• Others

Global Pancreatic Cancer Treatment Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• Blood Test
• Biopsy
• Imaging Tests
• Others

Global Pancreatic Cancer Treatment Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Others

Global Pancreatic Cancer Treatment Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Specialty Clinics
• Homecare
• Others

Global Pancreatic Cancer Treatment Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Pancreatic Cancer Treatment Market Size & CAGR (2025-2032)

• North America (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Diagnosis, Route of Administration, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharmaceuticals International (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinopharm (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EMS S.A. (Brazil)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations